E-Newsletter - May 2021
American Society of Clinical Oncology



Alliance NCTN/NCORP/AFT at 2021 ASCO

The 57th Annual Meeting of the American Society of Clinical Oncology (ASCO) will convene online June 4-8, bringing together thousands of oncology professionals from around the world. This year's meeting theme is "Equity: Every Patient. Every Day. Everywhere." Studies spanning the spectrum of cancer prevention and care, from immunotherapy and precision medicine to survivorship, will be highlighted.  

Each year, ASCO attendees learn from leading-edge scientific presentations, including papers and talks from Alliance researchers, as well as thousands of scientific abstracts and research news developments. At this year's conference, Alliance investigators will present more than 15 abstracts, sharing the latest findings on breast cancer, head and neck cancer, lung cancer, GI and GU cancers, along with cancer control research. The Alliance will be well-represented with dozens of researchers participating on panels, discussing new research, and presenting posters.
 
Here's a snapshot of studies that Alliance researchers will present:

Breast Cancer—Local/Regional/Adjuvant

Alliance A011801
A011801 (CompassHER2 RD): Postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer
First author: Ciara C. O’Sullivan
Abstract #: TPS595
J Clin Oncol 39, 2021 (suppl 15; abstr TPS595)

ACOSOG-Z1031
Evaluation of sensitivity to endocrine therapy index (SET2,3) for response to neoadjuvant endocrine therapy (NET) and subsequent prognosis
First author: W. Fraser Symmans
Abstract#: 580
J Clin Oncol 39, 2021 (suppl 15; abstr 580)

NCCTG-N9831
Outcome and immune landscape of HER2-positive invasive lobular carcinoma in the North Central Cancer Treatment Group (NCCTG) N9831 (Alliance) trial
First author: Saranya Chumsri
Abstract #: 535
J Clin Oncol 39, 2021 (suppl 15; abstr 535)

Central Nervous System Tumors
Alliance A071601
Alliance A071601: Phase II trial of BRAF/MEK inhibition in newly diagnosed papillary craniopharyngiomas                
First author: Priscilla K. Brastianos
Abstract #: 2000
J Clin Oncol 39, 2021 (suppl 15; abstr 2000)
Oral Presentation

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
CALGB-80802
Genetic predictor of severe sorafenib-induced diarrhea and hand-foot syndrome (HFS)          
First author: Julia C. F. Quintanilha
Abstract #: 3030
J Clin Oncol 39, 2021 (suppl 15; abstr 3030)

Gastrointestinal Cancer—Colorectal and Anal
CALGB-80405
Influence of dietary insulin scores on survival in patients with metastatic colorectal cancer (mCRC): Findings from CALGB (Alliance) 80405
First author: Katherine W. DiNardo     
Abstract #: 3568        
J Clin Oncol 39, 2021 (suppl 15; abstr 3568)

CALGB-80405
Dietary fat in relation to overall and progression-free survival among patients (pts) with advanced or metastatic colorectal cancer (CRC): Data from CALGB 80405 (Alliance)         
First author: Erin L. Van Blarigan
Abstract #: 3588
J Clin Oncol 39, 2021 (suppl 15; abstr 3588)

CALGB-80702
Early-onset stage II/III colorectal adenocarcinoma in the IDEA database: Treatment adherence, toxicities, and outcomes from adjuvant fluoropyrimidine and oxaliplatin
First author: Elisa Fontana
Abstract #: 3517
J Clin Oncol 39, 2021 (suppl 15; abstr 3517)

NCCTG-N0147
Association of plasma adiponectin with tumor infiltrating lymphocytes and survival in patients with stage III colon cancer (NCCTG N0147; Alliance)
First author: Frank A. Sinicrope
Abstract #: 3591
J Clin Oncol 39, 2021 (suppl 15; abstr 3591)

Genitourinary Cancer—Kidney and Bladder
Alliance A031801
A randomized trial of radium-223 (Ra-223) dichloride and cabozantinib in patients (pts) with advanced renal cell carcinoma (RCC) with bone metastases (RADICAL/Alliance A031801) 
First author: Rana R. McKay
Abstract #: TPS4593
J Clin Oncol 39, 2021 (suppl 15; abstr TPS4593)

Head and Neck Cancer
Alliance A091302
Randomized phase II study of sorafenib with or without everolimus in patients with radioactive iodine refractory Hürthle cell thyroid cancer (HCC) (Alliance A091302/ ITOG 1706)
First author: Eric Sherman
Abstract #: 6076
J Clin Oncol 39, 2021 (suppl 15; abstr 6076)

Health Services Research and Quality Improvement
AFT-25
Disparities in surveillance imaging after breast conserving surgery for primary DCIS
First author: Danalyn Byng
Abstract #: 6516
J Clin Oncol 39, 2021 (suppl 15; abstr 6516)

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
CALGB-50801
CALGB 50801 (Alliance): PET adapted therapy in bulky stage I/II classic Hodgkin lymphoma (cHL)
First author: Ann LaCasce      
Abstract #:7507
J Clin Oncol 39, 2021 (suppl 15; abstr 7507)
Oral Presentation | 6/7/2021, 11:30 am-2:30 pm ET

CALGB-51101
Myeloablative versus non-myeloablative consolidative chemotherapy for newly diagnosed primary central nervous system lymphoma:  Results of CALGB 51101 [Alliance]         
First author: Tracy T. Batchelor
Abstract #: 7506
J Clin Oncol 39, 2021 (suppl 15; abstr 7506)
Oral Presentation         

Hematologic Malignancies—Plasma Cell Dyscrasia
Alliance A231602CD
Assessing financial difficulty in patients with multiple myeloma: Preliminary results of Alliance A231602CD
First author: Rena Conti
Abstract #: 8031
J Clin Oncol 39, 2021 (suppl 15; abstr 8031) 

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
CALGB-30610
Phase 3 comparison of high-dose once-daily (QD) thoracic radiotherapy (TRT) with standard twice-daily (BID) TRT in limited stage small cell lung cancer (LSCLC): CALGB 30610 (Alliance)/RTOG 0538
First author: Jeffrey Bogart     
Abstract #: 8505
J Clin Oncol 39, 2021 (suppl 15; abstr 8505)
Oral Presentation | 6/6/2021, 8 am-11 am EDT

AFT-16
AFT-16: Phase II trial of neoadjuvant and adjuvant atezolizumab and chemoradiation (CRT) for stage III non-small cell lung cancer (NSCLC)
First author: Helen J. Ross
Abstract #: 8513
J Clin Oncol 39, 2021 (suppl 15; abstr 8513)

Symptoms and Survivorship
Alliance A151912, NCCTG N08CB
Neuropathy severity at the time of oxaliplatin treatment alteration in patients with colon cancer (Alliance A151912)
First author: Daniel Louis Hertz
Abstract #: 12090
J Clin Oncol 39, 2021 (suppl 15; abstr 12090)

AFT-28
The comparative effectiveness of direct oral anti-coagulants and low molecular weight heparins for prevention of recurrent venous thromboembolism in cancer: The CANVAS pragmatic randomized trial
Fist author: Deborah Schrag
Abstract #: 12020
J Clin Oncol 39, 2021 (suppl 15; abstr 12020)
 

 

For other articles in this issue of the Alliance E-News newsletter, see below.